Clozapine-Induced Myocarditis: Prevention and Considerations in Rechallenge

Psychosomatics

Volumn 56, Issue 6, 2015, Pages 685-690

  Cook, Sarah C ^a   Ferguson, Britnay A ^b   Cotes, Robert O ^a   Heinrich, Thomas W ^c   Schwartz, Ann C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GRADY HEALTH SYSTEM   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; BENZATROPINE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CLOZAPINE; DIGOXIN; HALOPERIDOL; LORAZEPAM; METOPROLOL; OLANZAPINE; QUETIAPINE; RISPERIDONE; TROPONIN I; VALPROIC ACID; NEUROLEPTIC AGENT;

ADULT; AGITATION; ARTICLE; ATRIAL FIBRILLATION; BEDTIME DOSAGE; BEHAVIOR DISORDER; BIPOLAR DISORDER; BIZARRE BEHAVIOR; BODY TEMPERATURE; BRAIN INJURY; CARDIOTOXICITY; CARDIOVERSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISORIENTATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ELECTROCARDIOGRAPHY; EVENING DOSAGE; FEMALE; FEVER; HOSPICE; HOSPITAL ADMISSION; HUMAN; INTELLECTUAL IMPAIRMENT; MEDICAL RECORD REVIEW; MORNING DOSAGE; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIMAL DRUG DOSE; PNEUMONIA; PULSE RATE; SCHIZOAFFECTIVE PSYCHOSIS; SEDATION; SIDE EFFECT; SINUS RHYTHM; TACHYCARDIA; TREATMENT RESPONSE; CHEMICALLY INDUCED;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; FEMALE; HUMANS; MYOCARDITIS;

EID: 84955215512     PISSN: 00333182     EISSN: 15457206     Source Type: Journal    
DOI: 10.1016/j.psym.2015.07.002     Document Type: Article

References (25)

1. Kilian J.G., Kerr K., Lawrence C., Celermajer D.S. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999, 354(9193):1841-1845.
2. Ronaldson K.J., Fitzgerald P.B., McNeil J.J. Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatr Scand 2015, http://dx.doi.org/10.1111/acps.12416.
3. Merrill D.B., Dec G.W., Goff D.C. Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 2005, 25(1):32-41.
4. Nielsen J., Correll C.U., Manu P., Kane J.M. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?. J Clin Psychiatr 2013, 74(6):603-613. [quiz 13].
5. Merrill D.B., Ahmari S.E., Bradford J.M., Lieberman J.A. Myocarditis during clozapine treatment. Am J Psychiatr 2006, 163(2):204-208.
6. Frustaci A., Verardo R., Sale P., et al. Hypersensitivity myocarditis induced by beta-blockers: an unexpected cause of abrupt deterioration in hypertrophic cardiomyopathy. Intensive Care Med 2007, 33(10):1848-1849.
7. Ronaldson K.J., Fitzgerald P.B., Taylor A.J., Topliss D.J., Wolfe R., McNeil J.J. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study. Schizophr Res 2012, 141(2-3):173-178.
8. Nielsen J., Damkier P., Lublin H., Taylor D. Optimizing clozapine treatment. Acta Psychiatr Scand 2011, 123(6):411-422.
9. Ronaldson K.J., Taylor A.J., Fitzgerald P.B., Topliss D.J., Elsik M., McNeil J.J. Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. J Clin Psychiatr 2010, 71(8):976-981.
10. Freudenreich O. Clozapine-induced myocarditis: prescribe safely but do prescribe. Acta Psychiatr Scand 2015, http://dx.doi.org/10.1111/acps.12425.
11. de Leon J., Tang Y.L., Baptista T., Cohen D., Schulte P.F. Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations. Acta Psychiatr Scand 2015, http://dx.doi.org/10.1111/acps.12421.
12. Ifteni P., Nielsen J., Burtea V., Correll C.U., Kane J.M., Manu P. Effectiveness and safety of rapid clozapine titration in schizophrenia. Acta Psychiatr Scand 2014, 130(1):25-29.
13. Varma S., Bishara D., Besag F.M., Taylor D. Clozapine-related EEG changes and seizures: dose and plasma-level relationships. Ther Adv Psychopharmacol 2011, 1(2):47-66.
14. Couchman L., Morgan P.E., Spencer E.P., Flanagan R.J. Plasma clozapine, norclozapine, and the clozapine:norclozapine ratio in relation to prescribed dose and other factors: data from a therapeutic drug monitoring service, 1993-2007. Ther Drug Monit 2010, 32(4):438-447.
15. Leucht S., Corves C., Arbter D., Engel R.R., Li C., Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373(9657):31-41.
16. Manu P., Sarpal D., Muir O., Kane J.M., Correll C.U. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res 2012, 134(2-3):180-186.
17. Seppala N., Kovio C., Leinonen E. Effect of anticholinergics in preventing acute deterioration in patients undergoing abrupt clozapine withdrawal. CNS Drugs 2005, 19(12):1049-1055.
18. Bray A., Reid R. Successful clozapine rechallenge after acute myocarditis. Aust N Z J Psychiatry 2011, 45(1):90.
19. Chow V., Feijo I., Trieu J., Starling J., Kritharides L. Successful rechallenge of clozapine therapy following previous clozapine-induced myocarditis confirmed on cardiac MRI. J Child Adolesc Psychopharmacol 2014, 24(2):99-101.
20. Jayathilake I., Singh A.K. Clozapine rechallenge after myocarditis. Australas Psychiatr 2009, 17(5):421-422.
21. Reid P., McArthur M., Pridmore S. Clozapine rechallenge after myocarditis. Aust N Z J Psychiatry 2001, 35(2):249.
22. Ronaldson K.J., Fitzgerald P.B., Taylor A.J., McNeil J.J. Observations from 8 cases of clozapine rechallenge after development of myocarditis. J Clin Psychiatr 2012, 73(2):252-254.
23. Rosenfeld A.J., Gibbs T., Ivie R., Clarke L., Merrill D.B. Successful clozapine retrial after suspected myocarditis. Am J Psychiatr 2010, 167(3):350-351.
24. Reinders J., Parsonage W., Lange D., Potter J.M., Plever S. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust N Z J Psychiatry 2004, 38(11-12):915-922.
25. Hassan I., Brennan A., Carroll A., Dolan M. Monitoring in clozapine rechallenge after myocarditis. Australas Psychiatr 2011, 19(4):370-371.